Table 3.

Summary of analyses conducted comparing genotype or haplotype to PSA, survival, peripheral neuropa and neutropenia following docetaxel.

Genotype or Haplotype	Treatment	Effect	P Value
Endpoint - PSA Prior to Study
1236C>T	Combined arms	none	NS*
2677G>T/A	Combined arms	none	NS*
3435C>T	Combined arms	Lower PSA with ABCB1 3435CT genotype	0.0001*
Diplotype 1–3 vs. 4–5	Combined arms	none	NS*
Diplotype 6–7 vs. 8 vs. 9–10	Combined arms	Higher PSA with diplotypes 9-10	0.0004*
Endpoint - Overall Survival
1236C>T	Doc.	none	NS**
	Doc. & Thal.	Lower survival with CT, TT genotypes vs. CC	0.0028**
2677G>T/A	Doc.	none	NS**
	Doc. & Thal.	Lower survival with GT, GA, TT genotypes vs.GG	0.018**
3435C>T	Doc.	none	NS**
	Doc. & Thal.	none	NS**
Diplotype 1–3 vs 4–5	Doc.	Lower survival with Diplotypes 4–5	0.0017***
	Doc. & Thal.	Lower survival with Diplotypes 4–5	0.045***
Diplotype 6–7 vs 8–10	Doc.	none	NS***
	Doc. & Thal.	Lower survival with Diplotypes 8–10	0.04***
Endpoint - Peripheral Neuropathy
1236C>T	Doc.	none	NS**
	Doc. & Thal.	none	NS**
2677G>T/A	Doc.	none	NS**
	Doc. & Thal.	More rapid neuropathy onset with 2677GT,	0.0070**
3435C>T	Doc.	none	NS**
	Doc. & Thal.	none	NS**
Diplotype 1–3 vs 4–5	Doc.	none	NS**
	Doc. & Thal.	none	NS**
Diplotype 6–7 vs 8–10	Doc.	none	NS**
	Doc. & Thal.	none	NS**
Endpoint - Neutropenia
1236C>T	Doc.	none	NS****
	Doc. & Thal.	none	NS****
2677G>T/A	Doc.	none	NS****
	Doc. & Thal.	none	NS****
3435C>T	Doc.	none	NS****
	Doc. & Thal.	none	NS****
Diplotype 1–3 vs. 4–5	Doc.	none	NS****
	Doc. & Thal.	none	NS****
Diplotypes 6–9 vs. 10	Doc.	No association, although only a single individual with diplotype 10 was observed.	NS****
	Doc. & Thal.	Diplotype 10 was associated with neutropenia	0.049*****
	Combined arms	Combined group trended towards an association with neutropenia	0.053*****

^*Kruskal-Wallis Test or Wilcoxon Rank-Sum test as appropriate

^**Log-Rank test

^***Cox model

^****Fisher's Exact Test

^*****Cochran-Armitage Trend Test